ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

ResMed’s stock has surged but faces potential risks from GLP-1 drugs. Find out why RMD stock remains a Hold as investors ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Zepbound's huge success is largely why investors are bullish ... Unsurprisingly, Intuitive Surgical has been one of the best ...

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast Johnson ... for widely-used blood oxygen monitoring devices to improve their performance across skin tones ...

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse ...

The highest dose of Zepbound has shown 25% weight loss over ... drug MariTide as a single dose in a convenient autoinjector device with a monthly and maybe less frequent dosing, a key feature ...